Hemogenyx Pharmaceuticals PLC Conditional Placing to raise GBP2,500,000 (6624M)
May 12 2020 - 8:22AM
UK Regulatory
TIDMHEMO
RNS Number : 6624M
Hemogenyx Pharmaceuticals PLC
12 May 2020
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 ("MAR"). In addition,
market soundings (as defined in MAR) were taken in respect of the
Placing with the result that certain persons became aware of inside
information (as defined in MAR), as permitted by MAR. This inside
information is set out in this announcement. Therefore, those
persons that received inside information in a market sounding are
no longer in possession of such inside information relating to the
Company and its securities.
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Conditional Placing to raise GBP2,500,000
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group, is pleased to announce that the Company has raised
GBP2,500,000 (before expenses) through an oversubscribed placing of
35,714,286 ordinary shares of 1p each (the "Placing Shares") at a
price of 7p per share (the "Placing Price"). The fundraise is
conditional on shareholders approving the special resolution to be
proposed at the Company's Annual General Meeting ("AGM") to be held
on 4 June 2020 inter alia allowing the Directors to issue equity
securities for cash.
The funds raised will be used to:
-- progress the Company's studies into the use of its advanced
humanized mice for the potential development of human neutralizing
antibodies to be used against COVID-19 and related COVID-19
work;
-- to advance IND-enabling studies for HEMO-CAR-T, the Company's
product candidate which is being developed as a potential blood
cancer treatment; and
-- for general working capital purposes.
Dr. Vladislav Sandler, Chief Executive Officer, commented, "We
are gratified by the greater recognition that is now being given to
the work that Hemogenyx is doing. We have raised these funds to
support two initiatives that we have announced: our recently
initiated studies into the use of our advanced humanized mice in
the development of new treatments to fight viral infection, in
particular isolating human neutralizing antibodies in the fight
against COVID-19, and our ongoing work into the development of
HEMO-CAR-T, which could , if successful, provide a new and
potentially effective treatment for AML and other blood cancers.
"
Admission
The Company has conditionally raised GBP2,500,000 before
expenses at the Placing Price through the issue of the Placing
Shares subject to shareholders passing the special resolutions at
the Company's AGM to be held on 4 June 2020 giving the Directors
the authority to issue the Placing Shares.
An application will be made for the Placing Shares to be
admitted to the Official List of the UK Listing Authority by way of
a Standard Listing ("Admission") and it is expected that Admission
will become effective and that dealing in the Placing Shares will
commence on or around 5 June 2020. The Placing Shares will rank
pari passu with the existing ordinary shares of the Company.
Total Voting Rights
Following Admission, the enlarged issued share capital of the
Company will comprise 432,968,255 ordinary shares of 1p each. No
ordinary shares are held in Treasury. The total number of voting
rights in the Company is therefore 432,968,255 . The figure of
432,968,255 ordinary shares may be used by shareholders of the
Company as the denominator for the calculations by which they will
determine if they are required to notify their investment in, or a
change in their interest in, the share capital of the Company under
the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEEAFSAFFSEEFA
(END) Dow Jones Newswires
May 12, 2020 09:22 ET (13:22 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024